Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming.

Geter PA, Ernlund AW, Bakogianni S, Alard A, Arju R, Giashuddin S, Gadi A, Bromberg J, Schneider RJ.

Genes Dev. 2017 Nov 15;31(22):2235-2249. doi: 10.1101/gad.305631.117. Epub 2017 Dec 21.

PMID:
29269484
2.

Endocrine Disruptors Leading to Obesity and Related Diseases.

Petrakis D, Vassilopoulou L, Mamoulakis C, Psycharakis C, Anifantaki A, Sifakis S, Docea AO, Tsiaoussis J, Makrigiannakis A, Tsatsakis AM.

Int J Environ Res Public Health. 2017 Oct 24;14(10). pii: E1282. doi: 10.3390/ijerph14101282. Review.

3.

Molecular pathways of oestrogen receptors and β-adrenergic receptors in cardiac cells: Recognition of their similarities, interactions and therapeutic value.

Machuki JO, Zhang HY, Harding SE, Sun H.

Acta Physiol (Oxf). 2018 Feb;222(2). doi: 10.1111/apha.12978. Epub 2017 Oct 30. Review.

4.

Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).

Schoeberl B, Kudla A, Masson K, Kalra A, Curley M, Finn G, Pace E, Harms B, Kim J, Kearns J, Fulgham A, Burenkova O, Grantcharova V, Yarar D, Paragas V, Fitzgerald J, Wainszelbaum M, West K, Mathews S, Nering R, Adiwijaya B, Garcia G, Kubasek B, Moyo V, Czibere A, Nielsen UB, MacBeath G.

NPJ Syst Biol Appl. 2017 Jan 5;3:16034. doi: 10.1038/npjsba.2016.34. eCollection 2017. Review.

5.

Endometrial receptivity in the eutopic endometrium of women with endometriosis: it is affected, and let me show you why.

Lessey BA, Kim JJ.

Fertil Steril. 2017 Jul;108(1):19-27. doi: 10.1016/j.fertnstert.2017.05.031. Epub 2017 Jun 14. Review.

PMID:
28602477
6.

Quantification of hypoxia-related gene expression as a potential approach for clinical outcome prediction in breast cancer.

El Guerrab A, Cayre A, Kwiatkowski F, Privat M, Rossignol JM, Rossignol F, Penault-Llorca F, Bignon YJ.

PLoS One. 2017 Apr 21;12(4):e0175960. doi: 10.1371/journal.pone.0175960. eCollection 2017.

7.

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.

Bredemeier M, Kasimir-Bauer S, Kolberg HC, Herold T, Synoracki S, Hauch S, Edimiris P, Bankfalvi A, Tewes M, Kimmig R, Aktas B.

Mol Med Rep. 2017 May;15(5):2957-2968. doi: 10.3892/mmr.2017.6415. Epub 2017 Mar 30.

8.

Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway.

Zheng Y, Jiang L, Hu Y, Xiao C, Xu N, Zhou J, Zhou X.

BMC Cancer. 2017 Feb 28;17(1):161. doi: 10.1186/s12885-017-3139-2.

9.

SGK3 sustains ERα signaling and drives acquired aromatase inhibitor resistance through maintaining endoplasmic reticulum homeostasis.

Wang Y, Zhou D, Phung S, Warden C, Rashid R, Chan N, Chen S.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1500-E1508. doi: 10.1073/pnas.1612991114. Epub 2017 Feb 7.

10.

ERK-mediated NF-κB activation through ASIC1 in response to acidosis.

Chen B, Liu J, Ho TT, Ding X, Mo YY.

Oncogenesis. 2016 Dec 12;5(12):e279. doi: 10.1038/oncsis.2016.81.

11.

Toosendanin Exerts an Anti-Cancer Effect in Glioblastoma by Inducing Estrogen Receptor β- and p53-Mediated Apoptosis.

Cao L, Qu D, Wang H, Zhang S, Jia C, Shi Z, Wang Z, Zhang J, Ma J.

Int J Mol Sci. 2016 Nov 18;17(11). pii: E1928.

12.

Minireview: The Link Between ERα Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer.

Légaré S, Basik M.

Mol Endocrinol. 2016 Sep;30(9):965-76. doi: 10.1210/me.2016-1072. Epub 2016 Jul 20. Review.

13.

Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.

She QB, Gruvberger-Saal SK, Maurer M, Chen Y, Jumppanen M, Su T, Dendy M, Lau YK, Memeo L, Horlings HM, van de Vijver MJ, Isola J, Hibshoosh H, Rosen N, Parsons R, Saal LH.

BMC Cancer. 2016 Aug 2;16:587. doi: 10.1186/s12885-016-2609-2.

14.

The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase.

Hoeflich KP, Guan J, Edgar KA, O'Brien C, Savage H, Wilson TR, Neve RM, Friedman LS, Wallin JJ.

Genes Cancer. 2016 Mar;7(3-4):73-85. doi: 10.18632/genesandcancer.100.

15.

Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.

Kangaspeska S, Hultsch S, Jaiswal A, Edgren H, Mpindi JP, Eldfors S, Brück O, Aittokallio T, Kallioniemi O.

BMC Cancer. 2016 Jul 4;16:378. doi: 10.1186/s12885-016-2452-5.

16.

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.

Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R.

Mol Cancer Res. 2016 May;14(5):470-81. doi: 10.1158/1541-7786.MCR-15-0423. Epub 2016 Mar 10.

17.

Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem.

Luqmani YA, Alam-Eldin N.

Med Princ Pract. 2016;25 Suppl 2:28-40. doi: 10.1159/000444451. Epub 2016 Feb 5. Review.

18.

Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway.

Lin CH, Chang CY, Lee KR, Lin HJ, Chen TH, Wan L.

BMC Cancer. 2015 Dec 16;15:958. doi: 10.1186/s12885-015-1965-7.

19.

Optimal management of hormone receptor positive metastatic breast cancer in 2016.

Reinert T, Barrios CH.

Ther Adv Med Oncol. 2015 Nov;7(6):304-20. doi: 10.1177/1758834015608993. Review.

20.

mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation.

Alayev A, Salamon RS, Berger SM, Schwartz NS, Cuesta R, Snyder RB, Holz MK.

Oncogene. 2016 Jul 7;35(27):3535-43. doi: 10.1038/onc.2015.414. Epub 2015 Nov 2.

Supplemental Content

Support Center